Ozempic 2 mg solution for injection in pre-filled pen

DRUG2 trials

Sponsors

Novo Nordisk A/S, Radboud universitair medisch centrum Stichting

Conditions

Diabetic foot ulcerParticipants with T2D and overweight

Phase 3

Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insuline glargine in participants with type 2 diabetes and overweight

CompletedCTIS2024-510612-75-00

Novo Nordisk A/SParticipants with T2D and overweight

Start: 2022-08-31End: 2025-04-01Target: 398Updated: 2025-03-12

Phase 4

Healing Diabetic Foot Ulcers with Semaglutide

Not yet recruitingCTIS2025-524738-24-00

Radboud universitair medisch centrum StichtingDiabetic foot ulcer

Target: 70Updated: 2026-03-30